Vir Biotechnology Files Offering Registration with 30-Day Over-Allotment Option
Vir Biotechnology has filed to offer common stock under its existing shelf registration, granting underwriters a 30-day over-allotment option. Net proceeds will finance clinical pipeline advancement, working capital and general corporate purposes.
1. Proposed Offering Details
Vir Biotechnology has filed a prospectus supplement under its shelf registration statement to sell shares of its common stock in a public offering. The company has also granted underwriters a 30-day option to purchase additional shares to cover overallotments.
2. Use of Proceeds
The net proceeds from the offering are intended to fund ongoing clinical development programs, bolster working capital and support general corporate purposes. This capital raise aims to ensure adequate runway for key pipeline assets.
3. Underwriter Option
Underwriters will have a 30-day over-allotment option to acquire additional shares at the public offering price. This provision provides flexibility to stabilize trading and accommodate additional investor demand if needed.